GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

GSK will hand over $1.2 bil­lion in up­front cash to li­cense a close­ly-watched can­di­date for fat­ty liv­er dis­ease from Boston Phar­ma­ceu­ti­cals.

The drug in ques­tion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER